Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.071 -0.029 (-2.63%)
Streaming Delayed Price Updated: 3:08 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon (LXRX) Q2 Revenue Soars 1,706%
Via The Motley Fool
Topics Intellectual Property
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q2 2025 Earnings: Revenue Soars 482% Above Estimates, Stock Gains 9.5%
Lexicon Pharmaceuticals (LXRX) reports strong Q2 2025 earnings with $28.9M revenue, beating estimates by 482%. Stock rises 9.5% on profit surprise and pipeline progress. 
Via Chartmill
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
A Preview Of Lexicon Pharmaceuticals's Earnings
 
Via Benzinga
Top 2 Health Care Stocks That May Crash This Month
 
Via Benzinga
Curious about the most active stocks on Monday?
Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today. 
Via Chartmill
Earnings Scheduled For May 13, 2025
 
Via Benzinga
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst
U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket. 
Via Benzinga
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting... 
Via Benzinga
Topics Economy
Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics
Via AB Newswire
Topics Intellectual Property
Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Friday's session: most active stocks
Curious about the most active stocks on Friday? Find out which stocks are dominating the market action! 
Via Chartmill
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Traders are paying attention to the gapping stocks in Friday's session.
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Top movers in Friday's pre-market session
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
The company is looking for drugs it can add to Wegovy to improve the amount of weight lost. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.